Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report

Ochi, Shinichiro; Inoue, Shigetaka; Yoshino, Yuta; Shimizu, Hideaki; Iga, Jun‐ichi; Ueno, Shu‐ichi

doi:10.9758/cpn.2019.17.4.559

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several case reports have described asenapine’s high efficacy for patients with severe psychopathology including DSP [ 6 , 7 , 25 ]. The reported patients were all treated with asenapine 20 mg; the chlorpromazine equivalent- dose is 800 mg. Our present two patients’ symptoms were also successfully controlled with similar dose of asenapine.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases

Kanahara

Kimura

Kinoshita

et al. 2023

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Dopamine supersensitivity psychosis (DSP) is an unstable clinical condition observed in individuals with schizophrenia who have been treated with an antipsychotic medication at a high dosage and/or for a long period. An up-regulation of dopamine D2 receptors (DRD2) is thought to be involved in the essential pathology of DSP. An antipsychotic agent with both tight binding to DRD2 and a long half-life is generally effective for treating DSP, but a patient who meets the criteria of treatment-resistant schizophrenia sometimes needs treatment with clozapine. We report the case details of two patients whose DSP was not controlled with several antipsychotics but was successfully controlled with asenapine. Asenapine binds to a broad range of dopamine receptors and serotonin receptors, and it is thus distinct from other atypical antipsychotics. The unique profile of asenapine may contribute to the control of severe DSP symptoms in individuals with schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases

Kanahara

Kimura

Kinoshita

et al. 2023

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

show abstract

“…This was the second head-to-head trial, where also asenapine proved its efficacy and safety. A case report published by Ochi et al [30] in 2019, showed Efficacy of Asenapine in Schizophrenia patient resistant to Clozapine combined with Electroconvulsive Therapy. A severe treatment-refractory schizophrenic patient who did not respond to clozapine even with ECT, but recovered with asenapine monotherapy gradually.…”

Section: Discussionmentioning

confidence: 99%

A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia

Maitra

Bhattacharyya

Mukhopadhyay

et al. 2020

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Objective Schizophrenia is a serious disease characterized by impairment in the perception or expression of reality, leading to occupational and social dysfunction. The use of antipsychotic medication is now universal in the first-line treatment of schizophrenia. This study was undertaken to compare the efficacy of asenapine with a standard atypical antipsychotic, olanzapine in treating this disease. Methods It was designed as a single blind, randomized, controlled, parallel group, single centre Phase IV trial of a newer atypical antipsychotic, asenapine versus existing standard atypical antipsychotic, olanzapine. Total 80 subjects were enrolled as per eligibility criteria.Each recruited subject received daily treatment with the trial medication (Olanzapine 10 mg or Asenapine 10 mg daily) for duration of 12 weeks. BPRS, CGI-S, CGI-I, Laboratory parameters and compliance was assessed and analyzed. Continuous variables were compared by t test and non-parametric data was analyzed by Mann−Whitney U test and Wilcoxon signed rank test. Likely categorical variables were analyzed by chi-square test or Fisher’s exact test, as appropriate. Results The duration of schizophrenia at presentation was comparable in both the treatment groups. There was significant reduction of BPRS score between any two visits of each treatment groups. The decline in CGI-S and CGI-I scores was statistically significant ( p < 0.001) when compared between visits of any of the both treatment arms. Adherence to treatment was excellent for all patients. Conclusion Newer atypical antipsychotic asenapine is more effective than standard olanzapine in reducing the symptoms of schizophrenia in this study and further larger studies are to be done.

show abstract

Pharmacological Targets and Mechanisms of Action of Antipsychotic Substances in the Context of the Neurochemical Theory of the Pathogenesis of Schizophrenia

Kalitin

Спасов

Mukha

et al. 2022

Neurosci Behav Physi

View full text Add to dashboard Cite

Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report

Cited by 5 publications

References 20 publications

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases

Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases

A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia

Pharmacological Targets and Mechanisms of Action of Antipsychotic Substances in the Context of the Neurochemical Theory of the Pathogenesis of Schizophrenia

Contact Info

Product

Resources

About